Tenderwize
Zurück zur Suche

Discount Agreement for Choriongonadotropin alfa

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 279 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-10 - Choriongonadotropin alfa

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated value or framework maximum is provided. Bidders cannot assess potential revenue or pricing strategy.

Since all qualified applicants can participate, many competitors may join, potentially limiting market share for each c...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products containing Choriongonadotropin alfa to patients insured by TK, HEK, and hkk.
  • Conclusion of a discount agreement under § 130a Abs. 8 SGB V with uniform terms for all participating pharmaceutical entrepreneurs.
Vollständige Zusammenfassung anzeigen

This is an Open House procedure by Techniker Krankenkasse (TK) and associated health insurers for discount agreements on the active substance Choriongonadotropin alfa. The contract is open to all qualified pharmaceutical entrepreneurs under uniform terms, with no exclusivity. The maximum contract duration is 24 months from June 1, 2025 to May 31, 2027. Submissions can be made at any time during the period, but must be submitted via email with qualified electronic signature or by post. The estimated contract value is not provided. The notice clarifies this is not a public procurement procedure under EU directives; legal challenges fall under social courts.

Risiken

No estimated value or framework maximum is provided. Bidders cannot assess potential revenue or pricing strategy.

Since all qualified applicants can participate, many competitors may join, potentially limiting market share for each c...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of § 4 Abs. 18 AMG for the offered medicinal product.
  • Must have a registered office in Germany, another EU member state, or a EEA state (§ 9 Abs. 2 Satz 1 AMG).
  • Must hold a valid marketing authorisation for the relevant medicinal product or be otherwise entitled to place it on the market.

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria; contracts are offered to all qualified pharma entrepreneurs.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Discount Agreement for Choriongonadotropin alfa

Open House procedure for concluding discount agreements with all suitable pharmaceutical entrepreneurs for the active substance Choriongonadotropin alfa. Uniform terms apply; no exclusivity is granted.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria; contracts are offered to all qualified pharma entrepreneurs.

Frist

Deadline May 30, 2027

Vergabedetails

Veröffentlichungsdatum
22 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
262953-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3